Study of characteristics in advanced lung cancer patients in Italy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to systematically assess the demographic, clinical, radiological, pathological, and molecular characteristics of patients diagnosed with Stage IV lung cancer in Italy. It will involve a large cohort of consecutive patients referred to two tertiary referral centers. The study seeks to identify preferential associations between various characteristics at the time of diagnosis, which have not been specifically studied in this population before.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \>18 years
* Suspicion of lung cancer based on imaging (CT and/or PET/CT)
* Indication to a biopsy for diagnosis, staging and/or molecular profiling

Exclusion Criteria:

* Inability or unwillingness to provide a written informed consent
* ECOG performance status (\>3) which makes a tissue diagnosis unfeasible
* ASA 4 status
* TNM Stage I-III

Where it's running

• Interventional Pulmonology Division - Fondazione Policlinico Universitario A. Gemelli IRCCS
  Roma, Italy Recruiting
• Istituto Nazionale Tumori Regina Elena
  Roma, Italy Not yet recruiting
• Medical Oncology Division - Fondazione Policlinico Universitario Agostino Gemelli IRCCS
  Roma, Italy Not yet recruiting

Study contacts

• Principal investigator: Rocco Trisolini — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Study coordinator: Rocco Trisolini, MD
• Email: rocco.trisolini@policlinicogemelli.it
• Phone: 0630154163

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BL-M14D1 plus atezolizumab vs standard therapy in first-line extensive-stage small cell lung cancer

  A first-line treatment for adults with extensive-stage small cell lung cancer tests whether adding BL-M14D1 to atezolizumab and standard chemotherapy helps more than standard care.

  Recruiting at 7 sites Phase 3 SystImmune Inc. · Springdale, Arkansas and 61 other locations · NCT07625644

• Understand cancer cachexia subtypes in advanced cancers

  This study tests how cancer cachexia presents in people with advanced colorectal, pancreatic, or lung cancer to see if different subtypes relate to outcomes.

  Recruiting Kaiser Permanente · Pleasanton, California · NCT07776353

• 64Cu-DOTA-Pembrolizumab PET to See If Treatment Is Working in Stage IV NSCLC

  This study tests a new PET imaging agent paired with pembrolizumab to see if it can show which tumors are still responding in adults with stage IV NSCLC who are already receiving pembrolizumab.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT07619599

• Morning versus afternoon immunotherapy for advanced or metastatic solid tumors

  This trial tests whether giving standard immune checkpoint inhibitor therapy in the morning versus the afternoon changes outcomes for adults with advanced or metastatic solid tumors.

  Recruiting Phase 4 OHSU Knight Cancer Institute · Portland, Oregon · NCT07405086

• Advanced NSCLC with actionable mutations after targeted therapy and chemo: expanded Lung-MAP treatment

  This phase II trial tests whether sacituzumab govitecan alone, ivonescimab alone, or the combination of both can help people with advanced or recurrent NSCLC that has a targetable genetic change.

  Recruiting at 41 sites Phase 2 SWOG Cancer Research Network · Berkeley, California and 40 other locations · NCT07393555

• SX-682 with Atezolizumab for advanced or metastatic NSCLC

  This phase 2 trial tests whether combining SX-682 with atezolizumab can help people with advanced, metastatic, or recurrent NSCLC who have progressed after prior treatments.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07322341

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.